logo
First fossil hyena tracks found in South Africa – how expert animal trackers helped

First fossil hyena tracks found in South Africa – how expert animal trackers helped

Yahoo28-03-2025
'The art of tracking may well be the origin of science.' This is the departure point for a 2013 book by Louis Liebenberg, co-founder of an organisation devoted to environmental monitoring.
The connection between tracking in nature, as people have done since prehistory, and 'western' science is of special interest to us as ichnologists. (Ichnology is the study of tracks and traces.) We learned our skills relatively late in life. But imagine if we had learned as children and if, as adults, we tracked as if our lives depended on it? What additional visual and cognitive talents would we bring to our field work as scientists?
Our mission is to find and document the fossilised tracks and traces of creatures that existed during part of the Pleistocene Epoch, between 35,000 and 400,000 years ago, on the Cape coast of South Africa. Since 2008, through the Cape South Coast Ichnology project, based in the African Centre for Coastal Palaeoscience at Nelson Mandela University, more than 370 vertebrate tracksites have been identified. They have substantially complemented the traditional record of body fossils. Examples include trackways of giant tortoises and giraffe.
Given the challenges inherent in identifying such tracks, we wondered how hunters who've been tracking all their lives would view our work, and how age-old indigenous expertise might align with our approach.
Fortunately we could call on experts with these skills in southern Africa. The Ju/'hoansi (pronounced 'Juun-kwasi') San people of north-eastern Namibia are perhaps the last of southern Africa's indigenous inhabitants who retain the full suite of their ancient environmental skills. The Nyae Nyae conservancy in which they live gives them access to at least some of their historical land with its remaining wildlife. They still engage in subsistence hunting with bow and poisoned arrow and gather food that's growing wild.
A handful among them have been recognised as Indigenous Master Tracker, a title created by Liebenberg's CyberTracker initiative in recognition of their top-flight hunter-gatherer status. And so, late in 2023, the Master Trackers #oma ('Komma') Daqm and /uce ('Tchu-shey') Nǂamce arrived in Cape Town.
We were not the first to think along these lines. Ju/'hoansi Master Trackers have assisted scientists in the interpretation of hominin tracksites in French caves, and prehistoric tracks in the rock art record in Namibia. However, we knew that our often poorly preserved tracksites in aeolianites (cemented dunes) might present a stiffer challenge.
Our purpose was to compare our own interpretations of fossil trackways with those of the Master Trackers, and possibly find some we had overlooked. As we've set out in a recently published paper with the Ju/'hoansi trackers and our colleague Jan De Vynck as co-authors, they did exactly this, confirming the first fossil hyena trackway ever to be found.
The Late Pleistocene is not that far distant from the present (a mere 125,000 years), and many of the species that made tracks on the Cape south coast then are still with us. Some are extinct but have recognisable tracks, like the giant long-horned buffalo and giant Cape zebra.
We knew, though, that tracking in Kalahari sand, like the Ju/'hoansi do, is not the same as tracking on Pleistocene rock surfaces. Many of our tracks are preserved on the undersides of ceilings and overhangs, or are evident in profile in cliff exposures. Our track-bearing surfaces are usually small, and present no associated signs. We can't follow the spoor for any distance. We don't know at what time of day the tracks were made or the role of dew, and we have never succeeded in actually tracking down our quarry. Coprolites – fossilised droppings – are seldom found conveniently beside the tracks of the depositor.
We showed our new colleagues known fossil tracksites, without providing our own interpretations. #oma and /uce discussed these between themselves and presented their conclusions about what had made the tracks and how the animal had been behaving. We then shared our insights and our 3D photogrammetry data where applicable, and reached joint conclusions.
Soon they were identifying freshly exposed tracksites without our input, and were providing fascinating, new interpretations for sites which had puzzled us. For example, they saw ostrich tracks which we had missed, beside ostrich egg remnants, and concluded that we were probably looking at a fossilised ostrich nest. On another occasion they pointed out the distinctive track pattern of a scrub hare on the hanging wall of an eroded piece of cliff.
One of the most memorable experiences involved a 400,000-year-old trackway on a rock surface at Dana Bay, identified a few years earlier by local geologists Aleck and Ilona Birch. This rock had only been transiently exposed for a few days in the past decade, usually being covered by beach sand.
Our earlier interpretation had been that the trackmaker might have been a hyena, probably the brown hyena.
We were vindicated when our master tracker colleagues independently reached the identical conclusion. Examining our digital 3D images together fortified our collective judgement.
This was a big deal: it was the first fossil hyena trackway to be confidently identified, as previous examples had involved only individual tracks or poorly preserved possible trackway segments. Hyena trackways are distinctive: the forefoot tracks are substantially larger than those of the hindfoot.
Both of us are privileged to have university degrees and institutional affiliations. But there is another way in which acumen can be measured: the ability to use the ancient methods of discernment and pattern recognition to support and feed one's family and community through tracking, hunting and gathering.
What we have demonstrated, we believe, is a novel confluence of old and new ways to reveal fascinating features of the past. We use geological understanding, satellite technology, paleontological databases, tracking manuals and sophisticated dating methods. But hunter-gatherers see what escapes us and our drones: obscure strokes and enigmatic configurations on time-beaten surfaces. They tap an alternative knowledge base, both culturally received and cultivated from childhood.
The follow-through challenge must be to develop this partnership for mutual discovery and reward, understanding the past to better equip us for our uncertain future.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Charles Helm, Nelson Mandela University and Clive Thompson, Nelson Mandela University
Read more:
Tracking science: a way to include more people in producing knowledge
African communities have a lot of knowledge to share: researchers offer alternatives to Eurocentric ways of doing things
Traditional farming knowledge should be stored for future use: the technology to do this is available
Clive Thompson is a trustee of the Discovery Wilderness Trust, a non-profit organization that supports environmental conservation and the fostering of tracking skills.
Charles Helm does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference
Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference

Yahoo

time12-08-2025

  • Yahoo

Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will participate in a panel discussion and corporate presentation at the H.C. Wainwright Annual Ophthalmology Virtual Conference on August 13, 2025. Details of the presentations are as follows: 7:00 am ET, on-demand corporate presentation 11:00 am ET, 'Pivotal-Stage Assets for Retinal Disorders' panel discussion Webcast Link InstructionsA webcast of each presentation can be accessed under the "Events" tab on the investor relations section of the Belite Bio website at: The replays will be archived for 90 days following the presentation date. About Belite BioBelite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Media and Investor Relations Contact:Jennifer Wu ir@ Julie Fallonbelite@

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Associated Press

time11-08-2025

  • Associated Press

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

SAN DIEGO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2025, and provided a general business update. 'This quarter, we remained on track with the strategic objectives we outlined at the start of the year, including the completion of enrollment in our pivotal Phase 3 PHOENIX trial — an important milestone in our development efforts for people living with geographic atrophy,' said Dr. Tom Lin, Chairman and CEO of Belite Bio. 'We also received Breakthrough Therapy Designation for Tinlarebant for the treatment of Stargardt disease from the FDA, underscoring its potential as the first-ever treatment for this patient population and acknowledging the significant unmet need for people living with this debilitating disease. With the DRAGON trial on track to complete by the end of this year, we remain focused on advancing Tinlarebant toward key clinical and regulatory milestones.' Second Quarter 2025 Business Highlights and Upcoming Milestones: Clinical Highlights Tinlarebant (LBS-008) is an oral, potent, once-daily, retinol binding protein 4 (RBP4) antagonist that decreases RBP4 levels in the blood and reduces vitamin A (retinol) delivery to the eye without disrupting systemic retinol delivery to other tissues. Vitamin A is critical for normal vision but can accumulate as toxic byproducts in individuals affected with STGD1 and GA, the advanced form of dry age-related macular degeneration (AMD), leading to retinal cell death and loss of vision. Corporate Highlights Second Quarter 2025 Financial Results: Current Assets: As of June 30, 2025, the Company had $149.2 million in cash, liquidity funds, time deposits, and U.S treasury bills. R&D Expenses: For the three months ended June 30, 2025, research and development expenses were $11.0 million compared to $9.1 million for the same period in 2024. For the six months ended June 30, 2025, research and development expenses were $20.4 million compared to $15.8 million for the same period in 2024. The increase in research and development expenses in both the quarter and year-to-date was primarily attributable to (i) higher pass-through expenses related to the PHOENIX trial and manufacturing expenses payments, partially offset by lower DRAGON trial expenses and a development milestone payment for the completion of a phase 2 trial in 2024; (ii) an increase in share-based compensation expenses. G&A Expenses: For the three months ended June 30, 2025, general and administrative expenses were $6.5 million compared to $1.4 million for the same period in 2024. For the six months ended June 30, 2025, general and administration expenses were $12.7 million compared to $3.0 million for the same period in 2024. The increase in general and administrative expenses in both the quarter and year-to-date was primarily due to an increase in share-based compensation expenses. Other Income: For the three months ended June 30, 2025, other income was $1.3 million compared to $1.0 million for the same period in 2024. For the six months ended June 30, 2025, other income was $2.5 million compared to $1.4 million for the same period in 2024. The increase in both the quarter and year-to-date was attributed to interest from time deposits and U.S. treasury bills. Net Loss: For the three months ended June 30, 2025, the Company reported a net loss of $16.3 million, compared to a net loss of $9.5 million for the same period in 2024. For the six months ended June 30, 2025, the Company reported a net loss of $30.6 million, compared to a net loss of $17.4 million for the same period in 2024. Webcast Information Belite Bio will host a webcast on Monday, August 11, 2025, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update. To join the webcast, please visit A replay will be available for approximately 90 days following the event. About Belite Bio Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and Geographic Atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite's lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at Important Cautions Regarding Forward Looking Statements This press release contains forward-looking statements about future expectations and plans, as well as other statements regarding matters that are not historical facts. These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio's advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates, and any other statements containing the words 'expect', 'hope' and similar expressions. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Belite Bio's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the timing to complete relevant clinical trials and/or to receive the interim/final data of such clinical trials; the timing to submit trial data to regulatory authorities for drug approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Belite Bio's drug candidates; the potential efficacy of Tinlarebant, as well as those risks more fully discussed in the 'Risk Factors' section in Belite Bio's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Belite Bio, and Belite Bio undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Media and Investor Relations Contact: Jennifer Wu [email protected] Julie Fallon [email protected]

Steroid Abuse Withdrawal Symptoms Tied to Psychiatric Burden
Steroid Abuse Withdrawal Symptoms Tied to Psychiatric Burden

Medscape

time06-08-2025

  • Medscape

Steroid Abuse Withdrawal Symptoms Tied to Psychiatric Burden

San Francisco — The sexual dysfunction and depression commonly seen in men following withdrawal from anabolic steroid abuse are more closely tied to psychiatric burden than to hormonal levels, new research suggests. 'Psychiatric burden was the only factor found to be independently associated with these symptoms, and no association with hormonal levels. This highlights the importance of psychological interventions in the management of men wishing to cease androgen abuse,' Bonnie Grant, MD, a clinical research fellow at Imperial College London, London, England, said at ENDO 2025: The Endocrine Society Annual Meeting. Androgen abuse is 'a growing, global problem,' she said, noting that about 6.4% of men worldwide abuse anabolic steroids, increasing up to 20% in recreational gym users. The primary motivations are image and muscular enhancement. However, the practice confers a threefold higher mortality rate, predominantly from cardiac conditions such as cardiomyopathy, or from suicide. Few studies have examined the effects of stopping steroid use, which precipitates a rapid drop in testosterone levels. 'We have noticed through our clinical experience that often these men, when they stop, report a lot of symptoms. They feel very depressed. They feel like they've lost their sexual function. We wanted to know what predicts that,' Grant told Medscape Medical News . Psychiatric Comorbidity, Not Hormonal Levels, Linked to Steroid Withdrawal In their cross-sectional, observational study, Grant and colleagues recruited men from four sites in the UK, where personal nonprescription use of anabolic steroids is legal. They were divided into three groups: 50 nonusers of anabolic steroids, 125 current users, and 90 who had stopped using within the past year. 'We focused on the first year, as this has been shown to be a time period with high rates of relapse, often due to the severity of withdrawal symptoms,' Grant explained. The men had an average age of about 36.5 years. In the past user group, the average time since quitting was 4.5 months. At a single study visit, the participants all completed several questionnaires: one on androgen use, the International Index Erectile Function-15 (IIEF-15) for sexual function, the Beck Depression Inventory-II (BDI-II) for depression, Generalized Anxiety Disorder-7 for anxiety, and Short-Form-36 for quality of life. They also underwent fasted, morning blood testing with urine toxicology to verify claims of noncurrent use. Men in the current and past anabolic steroid use groups had significantly higher rates of psychiatric comorbidity, mainly depression and anxiety (27.2% of the current users and 24.4% of the past users vs 10.0% of the nonusers; P = .038). The use of illicit drugs, mainly cocaine and cannabis, was also greater in the current and past users (43.2% current and 47.7% past vs 22% nonusers; P = .007). As expected, men with current use had significantly higher total testosterone levels, with a mean of 72.2 nmol/L compared with 14.3 nmol/L in the past users and 20.6 nmol/L in the nonusers ( P < .001). The latter two did not differ significantly. Levels of luteinizing hormone and follicle-stimulating hormone were fully suppressed in the current users but had recovered in the past use group ( P < .001 for both). Men with past androgen abuse had significantly lower scores on the IIEF-15, indicating worse sexual function compared with the other two groups. Among past users, a total testosterone < 8 nmol/L had a positive predictive value (PPV) for sexual dysfunction of 73%, indicating that hypogonadism was relatively predictive of sexual dysfunction. However, the negative predictive value (NPV) was 48%, suggesting that a total testosterone level above this threshold does not reliably exclude sexual dysfunction, Grant said. Looking at mood symptoms, the past use group had significantly higher scores on the BDI-II, indicating worse mood symptoms. Testosterone levels did not correlate with BDI scores. In the past users, total testosterone < 8 nmol/L poorly predicted moderate-to-severe depression (PPV, 20%), although the NPV was higher (81%). In multivariate analysis, psychiatric comorbidity was the only independent predictor of symptoms among men who had quit abusing anabolic steroids in the past year ( P = .01 for sexual dysfunction; P < .0001 for mood disorders). Total testosterone levels were not independently associated with symptom scores. 'A Window of Opportunity' Asked to comment, session moderator Shalender Bhasin, MD, director of the Research Program in Men's Health: Aging and Metabolism at Brigham and Women's Hospital, Boston, pointed out that in addition to depression and anxiety, these men will often have other psychiatric conditions, including body image disorder. 'Anabolic steroid use has not become a national priority, and I think it should be, because we have seen an underground, invisible epidemic of body image disorders and anabolic steroid use,' he told Medscape Medical News . 'People say, 'well, where are the dead bodies?' The thing is that these are gateway drugs, and we are seeing high rates of suicides, and other mental health problems in young men. The tragedy is that the [National Institutes of Health] and academia have done little to deal with this growing societal problem, mostly among young men. It is equally important to address the co-occurring psychopathology as it is to treat the withdrawal symptoms,' he said. Bhasin, who is also professor of medicine at Harvard Medical School, Boston, added that when men try to quit anabolic steroid use, the severity of the withdrawal symptoms often leads to relapse, and a 'vicious cycle of [anabolic-androgenic steroid (AAS] use, withdrawal, and relapse. For this reason, AAS withdrawal hypogonadism needs to be managed carefully medically. This also offers a window of opportunity when the patients undergoing withdrawal may be amenable to getting off AAS use altogether.' Grant received a speaker's honorarium from Besins Healthcare. Bhasin reported receiving research grant support from AbbVie and Metro International Biotech for investigator-initiated research, with the grants managed by Brigham and Women's Hospital. He had served as a consultant to Besins and Versanis and has an equity interest in XYone Therapeutics.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store